Michael Overduin, Director
Michael directs Science Capital, which he co-founded in 2010 to bring together scientists and business experts.
He is also a Professor of Structural Biology in Birmingham, where he established the Henry Wellcome Building as the UK's largest national research facility providing open access to superconducting magnets. Michael leads a laboratory studying protein mechanisms involved in cancer and genetic diseases, and collaborates with pharmaceutical companies to exploit novel therapeutic targets.
Michael Overduin graduated with a BSc in Biology from Wilfrid Laurier University, Canada in 1988. He received his PhD from The Rockefeller University in 1993. Michael then worked at the Ontario Cancer Institute at the University of Toronto until 1996 and the University of Colorado Health Sciences Center's Department of Pharmacology until 2003, when he joined the Division of Cancer Studies.
Among his awards are a Royal Society Wolfson Research Merit (2004), Pew Scholar (1998), Basil O'Connor (1998) and Alumnus of the Year from Wilfrid Laurier University (1995). Michael has been a member of the BBSRC Biomolecular Sciences Grant Review Committee and Medical Research Council College of Experts. He is also an Associate Editor of the Journal of Chemical Biology and Drug Design. Michael also volunteers as the Honorary Secretary of the Lunar Society and Chair of its Science and Medicine Subcommittee. His projects include CureCancer to promote and support the development of new therapeutic agents and treatments and CAMSEED to discover drug molecules for cancer.
